1.Canadian Association of Emergency Physicians Committee on Thrombolytic Therapy for Acute Ischemic Stroke. Thrombolytic therapy for acute ischemic stroke. CJEM 2001;3(1):8–12.
3.Tissue Plasminogen Activator for Acute Ischemic Stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333(24):1581–7.
4.Kay, R, Wong, KS, Yu, YL, Chan, YW, Tsoi, TH, Ahuja, AT, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333(24):1588–93
5.Marler, JR, Tilley, BC, Lu, M, Brott, TG, Lyden, PC, Grotta, JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology 2000;55:1649–55.
6.Jorgensen, HS, Nakayama, H, Kammersgaard, LP, Raaschou, HO, Olsen, TS.Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model. BMJ 1999;319:288–9.
7.Hoffman, JR.Predicted impact of intravenous thrombolysis. Another trial is needed [letter]. BMJ 2000;320:1007.
8.Libman, RB, Wirkowski, E, Alvir, J, Rao, TH.Conditions that mimic stroke in the emergency department: implications for acute stroke trials. Arch Neurol 1995;52(11):1119–22.
9.Schriger, DL, Kalafut, M, Starkman, S, Krueger, M, Saver, JL.Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA 1998;279:1293–7.
10.Katzan, IL, Furlan, AJ, Lloyd, LE, Frank, JI, Harper, DL, Hinchey, JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283(19):1151–8.